Point-of-care diagnostics and lab-on-a-chip platformsprimary
1 project
DIAGORAS project (EUR 625K) focused on bedside diagnosis using centrifugal microfluidics and multiplexed lab-on-a-chip technology.
Organization
BIOVENDOR - LABORATORNI MEDICINA AS
Czech diagnostics SME developing biomarker assays, point-of-care devices, and reagent kits for infection, cancer, and neurodegeneration research.
Technology SMEhealthCZSME
H2020 projects
3
As coordinator
0
Total EC funding
€708K
Unique partners
28
What they do
Their core work
BioVendor is a Czech diagnostics company based in Brno that develops and manufactures reagents, assay kits, and diagnostic tools for laboratory medicine. Within EU research, they contribute industrial expertise in point-of-care diagnostics, biomarker detection, and microfluidic lab-on-a-chip platforms. Their role spans from rapid infection diagnostics to cancer biomarker development, serving as the commercial diagnostics partner that bridges research discoveries toward validated clinical products.
Core expertise
What they specialise in
Non-coding RNA cancer biomarkersemerging
1 project
RNADIAGON project developed diagnostic approaches using microRNA and PIWI-interacting RNA for colorectal, renal, and hepatocellular cancers.
1 project
DIAGORAS addressed oral and respiratory tract infections with antibiotic resistance identification from saliva samples.
Protein structural biology and immunoassayssecondary
1 project
InterTAU project involves tau protein characterization using NMR and cryo-EM, relevant to BioVendor's immunology reagent capabilities.
Evolution & trajectory
How they've shifted over time
Early focus
Rapid infection diagnostics
Recent focus
Cancer and neurodegeneration biomarkers
BioVendor's H2020 journey started with hardware-oriented rapid diagnostics — building microfluidic devices for bedside infection detection and antibiotic resistance screening (DIAGORAS, 2015-2019). From 2019 onward, the focus shifted toward molecular biomarkers: non-coding RNA diagnostics for oncology (RNADIAGON) and structural biology of neurodegenerative disease proteins (InterTAU). This evolution reflects a move from device-level diagnostics toward upstream biomarker discovery and validation, positioning the company deeper in the translational research pipeline.
BioVendor is moving from diagnostic device development toward molecular biomarker validation in oncology and neuroscience, suggesting future interest in precision medicine and companion diagnostics.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European18 countries collaborated
BioVendor consistently participates as a partner rather than a coordinator, joining consortia to provide industrial diagnostics expertise and commercial validation capacity. With 28 unique partners across 18 countries from just 3 projects, they operate in large, internationally diverse consortia — typical of MSCA-RISE networks and RIA projects. This pattern suggests they are a sought-after industry partner valued for translating research findings into diagnostic products.
Despite only 3 projects, BioVendor has built a remarkably wide network of 28 partners across 18 countries, reflecting participation in large MSCA mobility and research consortia. Their geographic reach spans well beyond Central Europe into a broad European and likely international network.
Why partner with them
What sets them apart
BioVendor brings something rare to consortia: a commercially operating diagnostics company that can take research-stage biomarkers and assays toward product development. Unlike academic partners who publish findings, BioVendor can manufacture reagent kits, validate assays at industrial scale, and bring products to the clinical market. For consortium builders, they fill the critical "industry exploitation" slot that reviewers look for in Horizon proposals.
Notable projects
Highlights from their portfolio
- DIAGORASLargest funded project (EUR 625K) combining microfluidics, multiplexed diagnostics, and antibiotic resistance detection in a single bedside platform.
- RNADIAGONRepresents BioVendor's pivot into molecular oncology diagnostics, focusing on non-coding RNA biomarkers across three major cancer types.
- InterTAUUnusual for a diagnostics company — involvement in fundamental structural biology (NMR, cryo-EM) of tau protein suggests interest in Alzheimer's diagnostic development.
Cross-sector capabilities
Infectious disease surveillance and antimicrobial resistance monitoringOncology companion diagnosticsNeuroscience and neurodegeneration research toolsMicrofluidics and lab-on-a-chip engineering
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →